• SenzaGen agreed to acquire 100% of UK non-animal immunotoxicology specialist Alcyomics for an initial GBP 2.12 million in cash.
• Two potential cash earn-outs are capped at GBP 0.83 million for performance milestones and GBP 1.05 million for net-debt reduction.
• Completion is expected around November 4, 2026, expanding the group's non-animal testing offering into preclinical drug development.
• Funding combines existing cash with SEK 25 million of convertible bonds issued to principal owner Eiffel Investment Group, carrying 5.5% annual interest.
• Alcyomics' revenue rose 46% to approximately GBP 1.49 million in fiscal 2025/2026, with an EBITDA margin of approximately 24%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SenzaGen AB published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.